Cytokinetics' drug sales jumped. Why is its operating loss still $167 million?

Cytokinetics is selling more of its first commercial medicine. MYQORZO sales reached $44.5 million in the third quarter, up from $25.3 million in the second. More doctors are prescribing the heart drug, and more patients have received it.

Yet the much smaller net loss needs a closer look. Research by Ticker Byline shows that the $116.1 million year-over-year reduction in net loss was smaller than a $121.2 million debt-conversion charge in last year's quarter. The operating loss was almost unchanged at $167.1 million.

The launch is gaining ground. The cost of building a commercial drug business and developing the next products is rising alongside it.

The U.S. drives the launch

MYQORZO, also known as aficamten, is approved for adults with symptomatic obstructive hypertrophic cardiomyopathy. U.S. sales rose to $43.1 million from $23 million in the previous quarter.

Germany contributed $1.4 million, down from $2.3 million. The earlier figure included initial inventory purchased by distributors following the June launch, making it a different comparison from ongoing patient demand.

By September 30, nearly 1,100 healthcare providers had prescribed MYQORZO and more than 2,800 patients had received it. In June, the corresponding cumulative figures were more than 700 providers and about 1,500 patients.

That broader reach matters for a medicine launched in the U.S. early this year. The next commercial steps include an expected U.K. launch in the fourth quarter and expansion into additional countries in 2027.

Why the smaller loss is not the whole story

Net loss fell to $190.1 million from $306.2 million a year earlier. But last year's result included the large charge from exchanging convertible debt. That charge did not recur this quarter.

At the operating level, the comparison was $167.1 million of loss against $166.8 million. Revenue growth was absorbed by higher costs, especially selling and administration, which reached $113.1 million from $69.5 million. Cytokinetics attributed that increase to launch spending and personnel costs. Research and development expenses were $99.3 million, up from $97.3 million.

There was progress compared with the immediately preceding quarter: the operating loss narrowed from $179.2 million in Q2. The distinction is between a launch gradually covering more costs and a dramatic improvement in the year-over-year bottom line.

Product costs also look unusually favorable. The quarter recorded a $454,000 credit in cost of goods sold, including a $1 million vendor credit related to drug-supply optimization. Some inventory costs had already been expensed before MYQORZO's approval. Those features make this quarter's product margin a poor guide to the cost of supplying future sales.

The next filing was already on the calendar

Cytokinetics still plans to seek U.S. approval for aficamten in non-obstructive HCM through a supplemental application in the fourth quarter. That timetable was already in its August update. The company now also expects a European application in early 2027.

The annual forecast for combined research, development, selling and administrative expenses remains $860 million to $890 million, unchanged from August.

The launch still needs funding

Cash and investments totaled $1.58 billion at September 30, compared with $1.70 billion in June. The company used $429.3 million of operating cash in the first nine months, versus $367.4 million a year earlier.

A completed May share offering brought in about $760.1 million net. A further $175 million Royalty Pharma loan tranche remained available through December 19. Cytokinetics says it expects to draw it unless more favorable funding meets its needs.

The Cytokinetics company profile tracks the sales rollout, spending forecast, debt and royalty obligations. For investors, the next question is how quickly wider prescribing turns into enough recurring sales to cover a larger commercial operation and the continuing research bill.